🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› EU
Clinical trial register · European Union · CTIS

Recently authorised EU trials

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12445 total CTIS records — a stated recency window, not the full historical archive. Synced 20 Sep 2026, 03:17 UTC
2500
Shown in this register
most recently authorised
12,445
Total on CTIS
full historical archive
745
Phase III
within the shown window
Top member states
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524
Narrow the registerReset
Phase
Phase I 558 Phase I/II 214 Phase II 726 Phase III 745 Phase IV 257
Lead sponsor
AstraZeneca AB 60 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 45 Novo Nordisk A/S 42
Member state
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524 Belgium 426 Czechia 327
All 28 states
726 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase II
Interleukin-1 inhibition to improve the response of myeloproliferative neoplasms resistant to cytoreductive treatment
2025-523921-17-00myeloproliferative neoplasms
Centre Hospitalier Regional Et Universitaire De Brest
Hemic and Lymphatic Diseases
France
02/07/2026
Phase II
18F-fluoro-ethyl-tyrosine (18FET) PET for difficult clinical situations in functional pituitary adenoma. A prospective, single arm, single center study. (FET-PIT)
2025-523829-17-00Patients (male or female) ≥18 years old with Suspected func…
Centre Hospitalier Universitaire De Lille
Diagnosis
France
02/07/2026
Phase II
IFCT-2501 IDEATION ctDNA-guIDEd consolidATION immunotherapy after chemoradiotherapy in patients with stage III non-small cell lung cancer
2025-522801-39-00Stage III Non Small Cell Lung Cancer
Intergroupe Francophone De Cancerologie Thoracique
Neoplasms
France
02/07/2026
Phase II
High-dose Insulin Euglycemic Therapy in Non-Toxic Acute Cardiogenic Shock.
2025-523858-13-01Non-toxic acute cardiogenic shock
Oslo Universitetssykehus HF
Cardiovascular Diseases
Norway
01/07/2026
Phase II
A Phase II, Randomized, Double-blind, 3-Period Cross-over, Dose‑ranging Study to Assess the Efficacy and Safety of Glycopyrronium (GP) versus Placebo in Participants of 4 to Less than 12 Years of Age with Asthma Receiving Background Budesonide and Formoterol Fumarate (BFF) (FAROS)
2025-524914-26-00Asthma
AstraZeneca AB
Respiratory Tract Diseases
Czechia, Poland, Hungary
01/07/2026
Phase II
A phase IIa, single-arm, single-center, open label, proof-of-concept trial evaluating increased frequency dosing of VCN-01 (zabilugene almadenorepvec) in combination with nab-Paclitaxel/Gemcitabine (GnP) in Patients with Newly-Diagnosed Metastatic Pancreatic Cancer (VIRAGE2)
2026-525566-21-00metastatic pancreatic adecarcinoma
Theriva Biologics S.L.
Neoplasms
Spain
30/06/2026
Phase II
C6461014 - A Phase 2 Interventional Study of PF-08634404 in Combination with Chemotherapy in Participants with Previously Untreated Transformed Small Cell Lung Cancer
2025-524686-24-00Small Cell Lung Cancer
Pfizer Inc.
Neoplasms
France, Italy, Spain
29/06/2026
Phase II
Randomised open-label pilot Study on Thiamine supplementation to REduce braiN injury associated with chronic Alcohol use in outpatients with alcohol use disorder : STRENA
2025-524148-36-00Alcoholism
Institut National De La Sante Et De La Recherche Medicale
Mental Disorders
France
29/06/2026
Phase II
A Master Protocol of a Phase II, Open-label, Multicenter, Global Platform Study to Evaluate the Safety and Efficacy of Immunotherapy With or Without Other Anticancer Drugs in Participants with Unresectable Stage III Non-small Cell Lung Cancer Planning to Undergo Concurrent Chemoradiotherapy (AQUARIUS)
2025-523599-21-00Non-small Cell Lung Cancer
AstraZeneca AB
Neoplasms
Spain, Germany
29/06/2026
Phase II
A Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety and Efficacy of MTX-474 in the Treatment of Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)
2025-523288-39-00Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Mediar Therapeutics Inc.
Immune System Diseases
Netherlands, Romania, Poland, France, Italy, Spain
29/06/2026
Phase II
“In vivo” biological standardization of the allergenic extracts Dermatophagoides pteronyssinus (DPT) and Dermatophagoides farinae (DF) in patients sensitized to them.
2026-525628-13-00IgE-mediated respiratory allergic disease due to the allerg…
Probelte Pharma S.L.
Disorders of Environmental Origin
Spain
26/06/2026
Phase II
An open-label multiple dose safety, tolerability and exploratory efficacy clinical trial of PST-611 in patients with geographic atrophy secondary to age-related macular degeneration
2025-525008-12-00Geographic atrophy secondary to age-related macular degener…
PulseSight Therapeutics
Eye Diseases
France
25/06/2026
Phase II
A Randomized, Double-blinded, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Activity, Safety, and Tolerability of SAR445399 in Adult Participants with Non-Cystic Fibrosis Bronchiectasis (NCFB).
2025-523403-29-00Non-cystic fibrosis bronchiectasis
Sanofi-Aventis Recherche & Developpement
Respiratory Tract Diseases
Poland, Spain, France, Netherlands, Germany
23/06/2026
Phase II
An Open-Label Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents with Relapsing-Remitting Multiple Sclerosis
2025-524164-37-00Relapsing-Remitting Multiple Sclerosis (RRMS)
F. Hoffmann-La Roche AG
Nervous System Diseases
Poland, Germany, France
23/06/2026
Phase II
A Phase IIb, Non-Profit, Open-label Trial for the Intrathecal Administration of AAV9/AP4M1 for Hereditary Spastic Paraplegia Type 50 (SPG50).
2025-524481-15-00Heriditary spastic paraplegia (SPG50)
Rigshospitalet, Elpida Therapeutics SPC
Nervous System Diseases
Denmark
23/06/2026
Phase II
Efficacy of asciminib in chronic phase CML patients with T315l mutations
2025-523491-23-00Chronic Myeloid Leukemia
Friedrich-Schiller-Universitaet Jena
Neoplasms
Germany
23/06/2026
Phase II
An Open-label, Single-Arm, Phase 2 Study to Evaluate Enfortumab Vedotin plus Pembrolizumab for Bladder Preservation in Participants with Muscle-invasive Bladder Cancer (EV-209).
2025-524488-18-00Muscle-invasive Bladder Cancer
Astellas Pharma Global Development Inc.
Neoplasms
Germany, France, Poland, Italy, Spain
22/06/2026
Phase II
A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Adult Participants with Moderately to Severely Active Ulcerative Colitis
2025-523479-49-00Colitis ulcerative
Merck Sharp & Dohme LLC
Digestive System Diseases
Italy, Greece, Netherlands, Poland, Germany, France
22/06/2026
Phase II
Open-Label Extension Study to Provide Continued Access to Avutometinib Alone or in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
2025-524713-88-00Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Verastem Inc.
Neoplasms
France
22/06/2026
Phase II
Psilocybin-Assisted Psychotherapy for Posttraumatic Stress Disorder in Military Veterans: A Pilot Feasibility Study
2025-521488-11-00Posttraumatic stress disorder
ARQ National Psychotrauma Centrum
Mental Disorders
Netherlands
22/06/2026
Phase II
Supplementary Oxygen Therapy after Limb Debridement and Reconstruction Surgery in Infected Extremity Fractures (SOLDIER): a pilot, non-blinded, randomized controlled trial
2026-525871-24-00Fracture-Related Infection
Amsterdam UMC Stichting
Bacterial Infections and Mycoses
Netherlands
22/06/2026
Phase II
A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 for the Treatment of Narcolepsy with Cataplexy (Narcolepsy Type 1)
2025-522587-33-00Narcolepsy with Cataplexy (NT1)
Takeda Development Center Americas Inc.
Nervous System Diseases
Spain, Italy, France
22/06/2026
Phase II
Pain Relief at Screening for Retinopathy of Prematurity - The PROPER study
2023-507975-23-01Retinopathy of prematurity
St. Olavs Hospital HF
Eye Diseases
Norway
22/06/2026
Phase II
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of AGA2115 in Adults with Type I, III, or IV Osteogenesis Imperfecta (OI)
2025-522951-24-00Osteogenesis Imperfecta
Angitia Inc. Ltd.
Musculoskeletal Diseases
Netherlands, France, Denmark
22/06/2026
Phase II
A Phase 2, Randomized, Double-blind, Placebo-controlled Crossover Study Evaluating the Efficacy and Safety of LTG-321 in Patients with Osteoarthritis of the Knee
2026-525966-22-00Osteoarthritis of the knee
Latigo Biotherapeutics Inc.
Musculoskeletal Diseases
Denmark
22/06/2026
Rows per page Showing 151–175 of 726
Previous 5 6 7 8 9 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-europe

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.